- All
- Product Name
- Product Keyword
- Product Model
- Product Summary
- Product Description
- Multi Field Search
 |
loading
1kits（10Vials）
| Availability: | |
|---|---|
▎Tesamorelin
As a synthetic growth hormone-releasing hormone (GHRH) analog, Tesamorelin demonstrates significant clinical value in the management of specific diseases. Its core therapeutic positioning is to intervene in the abnormal accumulation of abdominal fat in HIV-infected individuals caused by long-term antiretroviral therapy. This drug highly mimics the molecular action mode of endogenous GHRH, binds to the specific receptors on the surface of growth hormone cells in the anterior pituitary gland, activates the G protein-coupled signaling pathway, and then induces the pulsatile release of growth hormone (GH) from the anterior pituitary gland. With the continuous increase of GH concentration in the circulatory system, the synthesis process of insulin-like growth factor-I (IGF-I) in the liver and peripheral tissues is significantly activated. This key growth factor regulates the energy metabolism network of adipocytes - including enhancing the activity of lipolytic enzymes to promote visceral fat breakdown and inhibiting the expression of fatty acid synthase to reduce fat deposition - ultimately achieving the reconstruction of abnormal fat distribution and the reduction of abdominal fat load.
In addition to the fat-reducing effect on the target organs, the pharmacological effects of Tesamorelin generate multiple physiological benefits through the systemic regulation of the GH-IGF-I axis: at the level of body composition optimization, it promotes the amino acid uptake of skeletal muscle cells and activates the myofiber regeneration process mediated by satellite cells, maintaining or increasing the proportion of lean body mass, and thus having a positive regulatory effect on muscle strength. This effect is closely related to the enhanced protein synthesis and inhibited protein breakdown mediated by growth hormone; in the field of bone metabolism, this drug has a protective effect on bone mineral density through a dual mechanism of promoting the differentiation and maturation of osteoblasts and inhibiting the activity of osteoclasts, especially providing a potential intervention approach for the prevention of bone loss associated with chronic diseases. The above mechanisms of action indicate that Tesamorelin is not limited to the improvement of local fat accumulation but rather achieves the integrated regulation of the physiological functions of multiple systems throughout the body by targeting the endocrine metabolic axis.
▎Ipamorelin
As a synthetic pentapeptide compound, Ipamorelin, as an important member of the growth hormone secretagogue family, achieves precise regulation of the growth hormone secretion axis by virtue of its unique molecular structure design. This compound binds with high affinity to the growth hormone secretagogue receptor (GHS-R), activates the downstream signaling pathway, efficiently induces the pulsatile release of growth hormone (GH), and simultaneously promotes the gene expression and protein synthesis of insulin-like growth factor-1 (IGF-1). This dual mechanism of action not only regulates the energy metabolism process (including promoting amino acid uptake, accelerating protein synthesis, and optimizing fat catabolism) but also plays a positive regulatory role in tissue repair and growth by enhancing the cell proliferation signal.
In clinical studies, Ipamorelin has demonstrated multi-system regulatory effects. Its effect on improving gastrointestinal motility is manifested as accelerating the gastric emptying rate. Especially in the state of postoperative ileus, by promoting the peristaltic frequency and contraction intensity of gastrointestinal smooth muscles, it effectively relieves intestinal motor dysfunction. In the field of pain management, this compound regulates nociceptive signal transduction through both central and peripheral pathways and shows a significant relieving effect on non-inflammatory visceral pain and somatic pain. Its mechanism of action may involve the activation of the endogenous opioid peptide system and the regulation of ion channel activity.
Compared with traditional growth hormone secretagogues, the significant advantage of Ipamorelin lies in its high selectivity for growth hormone release. While effectively stimulating GH secretion, this compound has no significant effect on the secretion of other pituitary-adrenal axis hormones such as adrenocorticotropic hormone (ACTH) and cortisol, thus reducing the risk of adverse reactions caused by hormonal disorders. This pharmacological property endows it with the potential for precise intervention in the replacement therapy of growth hormone deficiency, and at the same time provides a new drug target for the research on the pathogenesis of gastrointestinal motility disorders and the optimization of pain diagnosis and treatment programs.
▎Summary
1. Growth Hormone Regulation
Synergistic Mechanism:
Tesamorelin stimulates the secretion of growth hormone (GH) from the anterior pituitary gland by activating the growth hormone-releasing hormone (GHRH) receptor, while Ipamorelin promotes the pulsatile secretion of GH by selectively activating the growth hormone secretagogue receptor (GHSR).
When used in combination, the two can enhance the secretion of GH from different pathways, forming a synergistic effect and thus significantly increasing the level of GH in the body.
Balance and Control of GH Secretion:
Ipamorelin avoids the risk of excessive GH stimulation by mimicking the natural pulsatile secretion pattern of GH, while Tesamorelin provides a stable basis for GH secretion through the GHRH pathway. This combined use can maintain the GH level while ensuring the rhythmicity and balance of its secretion.
2. Metabolic Optimization
Lipid Metabolism:
Tesamorelin reduces visceral fat by enhancing fat breakdown and improving lipid metabolism, while Ipamorelin further accelerates fat metabolism by promoting fatty acid oxidation. When used in combination, the two can jointly optimize lipid metabolism, reduce age-related fat accumulation, and improve insulin sensitivity.
Glucose Metabolism:
Tesamorelin reduces the risk of metabolic disorders by improving the efficiency of glucose utilization, while Ipamorelin protects muscle tissue and avoids energy loss through its anti-catabolic effect.
This synergistic effect helps maintain metabolic balance and supports healthy aging.
3. Tissue Support and Repair
Protein Synthesis and Cell Renewal:
Tesamorelin promotes tissue repair and regeneration by stimulating protein synthesis and cell renewal, while Ipamorelin prevents muscle breakdown by protecting the existing tissue structure. When used in combination, the two can provide comprehensive tissue support, both promoting the repair of damaged tissues and protecting the existing tissues from being damaged.
Anti-aging Effect:
The increase in GH level is closely related to the anti-aging effect. The combined use of Tesamorelin and Ipamorelin can delay cell aging, improve skin elasticity, reduce wrinkles, and support bone health.
4. Anti-aging and Cognitive Benefits
Neuroprotection and Cognitive Function:
GH plays an important role in brain function and neuroprotection. The combined use of these two peptides can improve cognitive function and reduce age-related cognitive decline by regulating the GH level.
Systemic Resilience:
By balancing GH secretion and optimizing metabolism, the combined use can enhance the systemic resilience of the body and support long-term health and functional capacity.
About The Author
The above-mentioned materials are all researched, edited and compiled by Cocer Peptides.
ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE SOLELY FOR INFORMATION DISSEMINATION AND EDUCATIONAL PURPOSES.
The products provided on this website are intended exclusively for in vitro research. In vitro research (Latin: *in glass*, meaning in glassware) is conducted outside the human body. These products are not pharmaceuticals, have not been approved by the U.S. Food and Drug Administration (FDA), and must not be used to prevent, treat, or cure any medical condition, disease, or ailment. It is strictly prohibited by law to introduce these products into the human or animal body in any form.
